Back to top
more

Alector (ALEC)

(Real Time Quote from BATS)

$2.46 USD

2.46
285,480

0.00 (0.00%)

Updated Aug 27, 2026 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alector Stock Plummets 63% in a Month: Here's What You Need to Know

by Zacks Equity Research

ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.

Zacks Equity Research

Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of +19.05% and +24.19%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Certara, Inc. (CERT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Certara (CERT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright

by Zacks Equity Research

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Zacks Equity Research

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of +33.33% and +177.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 30% and 23.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -44% and 38.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of 96.88% and 220.64%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?